soul trial semaglutide (NEJM 2025): Oral led to a 14% ↓ in major CV events vs placebo in T2DM with ASCVD or CKD — no ↑ in serious AEs. #Semaglutide #CardioDiabetes #updatesinmedicine What the SELECT trial of

[38] Its important to note that weight gain or loss is not necessarily an accurate marker of metabolic health

Paradoxically, in chronic hypertension models, low-dose TMAO improves systolic/diastolic function and reduces fibrosis by stabilizing myocardial protein structure (Huc et al., 2018)

Can you send me the coverage policy in writing?" WHAT TO EXPECT BY PLAN TYPE Anthem's 2025 Zepbound Coverage Here's the realistic coverage landscape for Anthem members in 2025: Coverage by Plan Type and Region 2025 GLP-1 Coverage Rollbacks Major Coverage Changes in 2025-2026 Several Blue Cross/Blue Shield plans (including Anthem affiliates) are tightening or eliminating GLP-1 weight loss coverage due to cost concerns: California Medi-Cal (Anthem): Ended all GLP-1 weight loss coverage on 1/1/2026

Subcutaneous (SubQ) Injections These injections target the fatty layer just below the skin and are slower-absorbing compared to IM injections

Glutathiones strong antioxidant properties make it suitable as a supplement, particularly in cases of unfavorable cell growth such as cancer tumors and lipomas

Helps maintain immune and mitochondrial health*1,4,6-9